Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qlife Holding AB (publ) (QLIFE.ST)
Helsingborg, SE
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.10% | +4.71% | +2.56% | -0.99% | +41.84% | -23.37% | -13.04% | -99.53% | -100.00% | -99.99% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+548.0% ★ Q1'26: -80.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-382.4% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-4.6% Q1'26: -20,019.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-5,982.7% Q1'26: -27,714.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%— Q1'26: -583.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-99.7% ★ Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.47× Q1'26: -0.40× (vs Q1'25)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
17.99M
est: 18.00M (0.0%)
|
244.0K
est: 1.00M (-75.6%)
|
50.0K
est: 3.00M (-98.3%)
|
324.0K
est: 66.00M (-99.5%)
|
116.00M
116.00M – 116.00M
+75.8% YoY
|
168.00M
168.00M – 168.00M
+44.8% YoY
|
| EBITDA |
-78.05M
est: -17.37M (-349.3%)
|
-150.51M
est: -965.2K (-15,493.7%)
|
-12.46M
est: -2.93M (-324.8%)
|
-18.11M
est: -64.51M (+71.9%)
|
-113.37M
-113.37M – -113.37M
-75.8% YoY
|
-164.19M
-164.19M – -164.19M
-44.8% YoY
|
| EBIT |
-96.12M
est: -18.00M (-434.0%)
|
-157.27M
est: -1.00M (-15,626.8%)
|
-12.93M
est: -3.00M (-330.9%)
|
-19.38M
est: -66.00M (+70.6%)
|
-116.00M
-116.00M – -116.00M
-75.8% YoY
|
-168.00M
-168.00M – -168.00M
-44.8% YoY
|
| Net Income |
-93.14M
est: -6.09T (+100.0%)
|
-159.96M
est: -1.37T (+100.0%)
|
-55.98M
est: -3.55B (+98.4%)
|
-20.56M
est: -2.37B (+99.1%)
|
-1.58B
-1.58B – -1.58B
+33.3% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
113.58M
est: 1.78B (-93.6%)
|
58.62M
est: 99.00M (-40.8%)
|
12.30M
est: 296.12M (-95.8%)
|
—
est: 6.51B (-100.0%)
|
11.45B
11.45B – 11.45B
+75.8% YoY
|
16.58B
16.58B – 16.58B
+44.8% YoY
|
| EPS |
-0.87
est: -1,557.02 (+99.9%)
|
-0.26
est: -349.53 (+99.9%)
|
-0.34
est: -283.87 (+99.9%)
|
-1.64
est: -189.25 (+99.1%)
|
-126.16
-126.16 – -126.16
+33.3% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Warthoe | Co-Founder & Chief Executive Officer | 436.0K | male |
| Lars Bangsgaard | Co-Founder & Chief Financial Officer | 146.0K | male |
| Peter Warthoe | Co-Founder & Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for QLIFE.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
